NVO Novo Nordisk

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

________________

 

FORM 6-K

________________

 

REPORT OF FOREIGN PRIVATE ISSUER

 

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

 

February 4, 2016

________________

 

NOVO NORDISK A/S

 (Exact name of Registrant as specified in its charter)

 

 

Novo Allé 

DK- 2880, Bagsvaerd 

Denmark

(Address of principal executive offices)

________________

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

 

Form 20-F [X]

Form 40-F [  ]

 

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes [  ]

No [X]

 

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-________

 

 

 

 

Trading in Novo Nordisk shares by board members, executives and associated persons on 3 February 2016

 

Bagsværd, Denmark, 4 February 2016 In accordance with Section 28a of the Danish Securities Trading Act, the company’s board members and executives have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons as reported by those persons to Novo Nordisk.

 

As from 2004, members of Novo Nordisk's Executive Management and other members of the Senior Management Board have participated in a long-term share-based incentive programme where a proportion of the calculated shareholder value creation has been allocated to a joint pool for the participants. For 2012, 487,730 shares were allocated to the joint pool and the market value of the scheme was expensed in the accounts for 2012. In accordance with the principles of the programme, the Board of Directors of Novo Nordisk A/S on 2 February 2016 evaluated that the conditions for release of the joint pool of shares have been fulfilled. Accordingly, the shares in the joint pool were transferred to 30 current and former members of senior management on 3 February 2016.

 

As of 2007, a number of key employees under senior management level have also participated in a share-based programme with similar performance criteria as the programme for senior management. A programme was established for 2012, and in line with the programme for senior management, the Board of Directors of Novo Nordisk A/S on 2 February 2016 evaluated that the conditions for release of the shares have been fulfilled and the shares were transferred to the participants on 3 February 2016 accordingly. An employee-elected member of the Board of Directors has participated in this programme and the reporting below reflects this participation.

 

 

Name	Liselotte Hyveled
Reason for reporting	Member of the Board of Directors (employee representative)
Financial instrument and ID code	Novo Nordisk B DK0060534915
Type of transaction	Other transaction (transfer of shares in accordance with long-term incentive programme)
Date of transaction	3 February 2016
Place of transaction	Nasdaq Copenhagen
Volume of transaction	2,000 shares
Total value of transaction	0 (transferred in accordance with the long-term incentive programme for 2012)

 

 

Name	Lars Rebien Sørensen
Reason for reporting	President and chief executive officer (CEO)
Financial instrument and ID code	Novo Nordisk B DK0060534915
Type of transaction	Other transaction (transfer of shares in accordance with long-term incentive programme)
Date of transaction	3 February 2016
Place of transaction	Nasdaq Copenhagen
Volume of transaction	41,110 shares
Total value of transaction	0 (transferred in accordance with the long-term incentive programme for 2012)

 

 

Name	Lars Rebien Sørensen
Reason for reporting	President and chief executive officer (CEO)
Financial instrument and ID code	Novo Nordisk B DK0060534915
Type of transaction	Sale of shares
Date of transaction	3 February 2016
Place of transaction	Nasdaq Copenhagen
Volume of transaction	30,000 shares
Total value of transaction	DKK 10,689,021

 

 

Name	Jesper Brandgaard
Reason for reporting	Executive vice president and chief financial officer (CFO)
Financial instrument and ID code	Novo Nordisk B DK0060534915
Type of transaction	Other transaction (transfer of shares in accordance with long-term incentive programme)
Date of transaction	3 February 2016
Place of transaction	Nasdaq Copenhagen
Volume of transaction	27,335 shares
Total value of transaction	0 (transferred in accordance with the long-term incentive programme for 2012)

 

 

Name	Jesper Brandgaard
Reason for reporting	Executive vice president and chief financial officer (CFO)
Financial instrument and ID code	Novo Nordisk B DK0060534915
Type of transaction	Sale of shares
Date of transaction	3 February 2016
Place of transaction	Nasdaq Copenhagen
Volume of transaction	27,335 shares
Total value of transaction	DKK 9,744,821

 

 

Name	Maziar Mike Doustdar
Reason for reporting	Executive vice president, International Operations
Financial instrument and ID code	Novo Nordisk B DK0060534915
Type of transaction	Other transaction (transfer of shares in accordance with long-term incentive programme)
Date of transaction	3 February 2016
Place of transaction	Nasdaq Copenhagen
Volume of transaction	4,000 shares
Total value of transaction	0 (transferred in accordance with the long-term incentive programme for 2012)

 

 

 

Name	Jerzy Gruhn
Reason for reporting	Executive vice president, Europe
Financial instrument and ID code	Novo Nordisk B DK0060534915
Type of transaction	Other transaction (transfer of shares in accordance with long-term incentive programme)
Date of transaction	3 February 2016
Place of transaction	Nasdaq Copenhagen
Volume of transaction	13,665 shares
Total value of transaction	0 (transferred in accordance with the long-term incentive programme for 2012)

 

 

Name	Jesper Høiland
Reason for reporting	Executive vice president, US
Financial instrument and ID code	Novo Nordisk B DK0060534915
Type of transaction	Other transaction (transfer of shares in accordance with long-term incentive programme)
Date of transaction	3 February 2016
Place of transaction	Nasdaq Copenhagen
Volume of transaction	13,665 shares
Total value of transaction	0 (transferred in accordance with the long-term incentive programme for 2012)

 

 

Name	Lars Fruergaard Jørgensen
Reason for reporting	Executive vice president and chief of staff
Financial instrument and ID code	Novo Nordisk B DK0060534915
Type of transaction	Other transaction (transfer of shares in accordance with long-term incentive programme)
Date of transaction	3 February 2016
Place of transaction	Nasdaq Copenhagen
Volume of transaction	13,665 shares
Total value of transaction	0 (transferred in accordance with the long-term incentive programme for 2012)

 

 

Name	Lars Fruergaard Jørgensen
Reason for reporting	Executive vice president and chief of staff
Financial instrument and ID code	Novo Nordisk B DK0060534915
Type of transaction	Sale of shares
Date of transaction	3 February 2016
Place of transaction	Nasdaq Copenhagen
Volume of transaction	5,000 shares
Total value of transaction	DKK 1,782,481

 

 

Name	Jakob Riis
Reason for reporting	Executive vice president, China, Pacific & Marketing
Financial instrument and ID code	Novo Nordisk B DK0060534915
Type of transaction	Other transaction (transfer of shares in accordance with long-term incentive programme)
Date of transaction	3 February 2016
Place of transaction	Nasdaq Copenhagen
Volume of transaction	13,665 shares
Total value of transaction	0 (transferred in accordance with the long-term incentive programme for 2012)

 

 

Name	Jakob Riis
Reason for reporting	Executive vice president, China, Pacific & Marketing
Financial instrument and ID code	Novo Nordisk B DK0060534915
Type of transaction	Sale of shares
Date of transaction	3 February 2016
Place of transaction	Nasdaq Copenhagen
Volume of transaction	8,000 shares
Total value of transaction	DKK 2,850,406

 

 

Name	Mads Krogsgaard Thomsen
Reason for reporting	Executive vice president and chief science officer (CSO)
Financial instrument and ID code	Novo Nordisk B DK0060534915
Type of transaction	Other transaction (transfer of shares in accordance with long-term incentive programme)
Date of transaction	3 February 2016
Place of transaction	Nasdaq Copenhagen
Volume of transaction	27,335 shares
Total value of transaction	0 (transferred in accordance with the long-term incentive programme for 2012)

 

 

Name	Mads Krogsgaard Thomsen
Reason for reporting	Executive vice president and chief science officer (CSO)
Financial instrument and ID code	Novo Nordisk B DK0060534915
Type of transaction	Sale of shares
Date of transaction	3 February 2016
Place of transaction	Nasdaq Copenhagen
Volume of transaction	9,000 shares
Total value of transaction	DKK 3,208,465

 

 

 

Name	Henrik Wulff
Reason for reporting	Executive vice president, Product Supply
Financial instrument and ID code	Novo Nordisk B DK0060534915
Type of transaction	Other transaction (transfer of shares in accordance with long-term incentive programme)
Date of transaction	3 February 2016
Place of transaction	Nasdaq Copenhagen
Volume of transaction	13,665 shares
Total value of transaction	0 (transferred in accordance with the long-term incentive programme for 2012)

 

Below please find other trading in shares issued by Novo Nordisk.

 

Name	Lotte Frost Holding ApS
Reason for reporting	Associated to a member of Executive Management, Lars Fruergaard Jørgensen
Financial instrument and ID code	Novo Nordisk B DK0060534915
Type of transaction	Sale of shares
Date of transaction	3 February 2016
Place of transaction	Nasdaq Copenhagen
Volume of transaction	4,030 shares
Total value of transaction	DKK 1,451,203

 

 

 

Definitions and background information:

 

Publication

Publication shall take place no later than two working days after the trading by board members or executives or notification of trading by associated persons. Publication is only required when the total amount of transactions of a specific board member/executive and his/her associated persons in any one calendar year has reached 5,000 euros.

 

Who are board members, executives and associated persons?

Board members and executives are members of the Board of Directors and Executive Management, respectively, of Novo Nordisk A/S. Associated persons are defined as the following persons associated to a board member/executive: 1) spouse or cohabitant, 2) children under the age of 18 years, 3) relatives defined as brothers, sisters, parents, grandparents etc, children, grandchildren etc who have shared the same household with a board member/executive for at least one year, and 4) any legal person, including a company, a foundation or a partnership, which is controlled directly or indirectly by a board member/executive and/or a person mentioned in 1)–3), or to which a board member/executive and/or a person mentioned in 1)–3) has managerial responsibilities or economic interests substantially equivalent to the legal person.

 

What is trading/transaction?

Trading is any kind of transaction, including shares purchased or otherwise acquired, shares sold or otherwise disposed, gifts, mortgages and grants and exercise of options, but not heritage.

 

What is financial instrument and ID code?

Financial instrument includes shares listed on the Nasdaq Copenhagen and ADRs listed on New York Stock Exchange, except for ADRs held in 401(k) retirement plan by US- based employees. The ID code is the code (ISIN DK0060534915) of the Novo Nordisk share on the Nasdaq Copenhagen or the code (NVO) on New York Stock Exchange.

 

What is date and place of transaction?

Date of transaction is the actual transaction date. The place of transaction is the actual place of transaction, ie Nasdaq Copenhagen or New York Stock Exchange.

 

What is volume and value of transaction?

The volume of transaction is the number of shares (of DKK 0.20 nominal value) or other financial instruments traded. The transaction value is the number of shares traded multiplied by the transaction price. The exchange rate of the Danish Central Bank (Nationalbanken) on the date of transaction is used for calculating the transaction value in DKK in case of ADRs listed on New York Stock Exchange.

 

 

 

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 40,300 people in 75 countries and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube

 

 

Further information

Media:
Anne Margrethe Hauge	+45 3079 3450	amhg@novonordisk.com
Ken Inchausti (US)	+1 609 514 8316	kiau@novonordisk.com
Investors:
Peter Hugreffe Ankersen	+45 3075 9085	phak@novonordisk.com
Daniel Bohsen	+45 3079 6376	dabo@novonordisk.com
Melanie Raouzeos	+45 3075 3479	mrz@novonordisk.com
Kasper Veje	+45 3079 8519	kpvj@novonordisk.com

 

 

 

 

 

 

 

 

Novo Nordisk A/S Investor Relations	Novo Allé 2880 Bagsværd Denmark	Telephone: +45 4444 8888	Internet: www.novonordisk.com CVR no: 24 25 67 90
		Company announcement No 09 / 2016

 

 

---

 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

 

Date: February 4, 2016

NOVO NORDISK A/S   Lars Rebien Sørensen, Chief Executive Officer